Small-Molecule Nootropic · Russian

Noopept: Russian Dipeptide Cognitive Enhancer (GVS-111)

A UK-focused, evidence-based comparison of Noopept and Dihexa — mechanism, benefits, dosing, side effects, legal status, and stacking.

Noopept (developmental code GVS-111) is a synthetic dipeptide nootropic developed in the 1990s at the Russian Institute of Pharmacology and registered in Russia as a prescription medicine for "asthenic disorders" and cognitive complaints. Chemically it is a proline-glycine dipeptide ethyl ester linked to a phenylacetyl group. It is widely marketed as being 1000 times more potent by weight than piracetam — a claim that is approximately accurate at the receptor-affinity level but does not mean it is 1000 times more clinically effective. Noopept is rapidly metabolised after oral or sublingual administration to cycloprolylglycine (CPG), an endogenous neuropeptide that is the actual mediator of most of its CNS effects.

What is Noopept?

Noopept is the brand name for ethyl N-phenylacetyl-L-prolylglycinate, a small dipeptide molecule developed at the Institute of Pharmacology of the Russian Academy of Medical Sciences in Moscow as a structural mimic of the endogenous neuropeptide cycloprolylglycine (CPG). After oral administration Noopept is rapidly hydrolysed to CPG, which is the active species at most CNS targets. Registered as a medicine in Russia (and a few other CIS markets) for use in cognitive impairment from cerebrovascular disease, post-concussion syndrome, "asthenic" disorders, and as a cognitive adjunct. Approximately 100+ published peer-reviewed papers exist, predominantly Russian, including small clinical trials and substantial preclinical work.

Chemistry: N-Phenylacetyl-L-prolylglycine ethyl ester · MW 318.37 g/mol · racetam-like dipeptide ester
Origin: Institute of Pharmacology RAMS, Moscow (Russia), 1990s
Primary route: Oral (sublingual or swallow); also intranasal
Pharmacokinetics: Plasma half-life of cycloprolylglycine (active metabolite) ~30 minutes; functional cognitive effects persist 3-4 hours per dose.
Class: Russian dipeptide nootropic · racetam-class metabolite

Mechanism of Action

Noopept (via its active metabolite CPG) acts on multiple CNS targets: positive allosteric modulation of AMPA glutamate receptors (the cognitive-enhancer mechanism shared with the racetam family); upregulation of BDNF and NGF expression in hippocampus and cortex over multi-day dosing; increased acetylcholine release in the forebrain; antioxidant and anti-apoptotic effects protecting neurons from ischaemic and toxic stress; reduction of beta-amyloid neurotoxicity in cell culture models; and modulation of stress-related corticosterone elevation. The combination of glutamatergic enhancement plus BDNF/NGF upregulation produces both an acute cognitive effect (felt within 30-60 minutes of dosing) and a cumulative effect that builds over 7-14 days of consistent use.

Proposed Benefits

Reported benefits include: improved working memory and cognitive stamina across demanding tasks (the acute glutamatergic / AMPA-modulator effect), better consolidation of new learning over multi-week courses (the BDNF/NGF effect), improved mood and reduced "brain fog", neuroprotective benefit after head injury or cerebrovascular events (the registered Russian indications), and a mild anxiolytic effect at moderate doses. Clinical use in Russia covers post-stroke cognitive recovery, post-concussion syndrome, "asthenic disorders" (a Russian diagnostic category covering chronic fatigue and reduced cognitive stamina), and adjunctive use in dementia. Healthy nootropic users typically report a clean cognitive lift without the stimulation of caffeine or modafinil, with the effect being more "clarity" than "energy".

Evidence Base

The evidence base is moderate in volume and concentrated in Russian-language journals, with limited Western replication. Key references: Ostrovskaya et al. 2014 (Frontiers in Pharmacology, English-language review of Noopept neuroprotection); Lyubitsev et al. 2014 (post-stroke cognitive recovery trial); Neznamov and Teleshova 2009 (mild cognitive impairment trial, n=53); Ostrovskaya et al. 2007 (anxiolytic and antidepressant effects); various Russian Phase 3 trials for the local registration. The strongest signal is mild cognitive enhancement in patients with documented cognitive impairment from cerebrovascular disease or post-concussion syndrome; the evidence in healthy enhancement-seeking populations is weaker. No FDA Phase 3 program has been completed.

Dosage & Administration

Russian approved dose: 10 mg orally 2-3 times per day (total 20-30 mg/day) for cognitive indications, typically for 30-60 day courses. Community nootropic protocols: typically 10-20 mg taken sublingually 1-3 times per day (10 mg morning, 10 mg early afternoon being the most common schedule). Cycling is debated — some users dose continuously for months, others cycle 8 weeks on / 4 weeks off. Sublingual administration is often preferred over swallowing because of better bioavailability (the active metabolite CPG forms equally either way but sublingual avoids first-pass effects). Standard form is the 10 mg or 20 mg powder, or pre-filled capsules; sublingual powder dissolves quickly under the tongue.

This is a community-reported protocol summary, not a medical recommendation. There is no established human dose. Consult a qualified healthcare professional before using any research compound.

Side Effects & Risks

Noopept's safety profile across 30+ years of Russian clinical use is reassuring. Reported acute effects are mild and uncommon: occasional irritability or restlessness at higher doses, sleep disturbance if taken late in the day (the AMPA-modulator mechanism is mildly arousing), mild headache (often dose-related and often resolved by adding a choline source like Alpha-GPC), and rare reports of mild anxiety. The compound is not addictive and has no documented withdrawal syndrome. Contraindications: active epilepsy (theoretical seizure-threshold concern with AMPA modulation, though no clinical signal), pregnancy/breastfeeding (no safety data), known hypersensitivity. Common interactions: can amplify the cognitive effects of choline sources, racetams, and modafinil; combine cautiously with stimulants to avoid over-arousal.

UK Legal Status

UK: not a controlled substance under the Misuse of Drugs Act 1971, not licensed as a medicine by the MHRA, but the legal position under the Psychoactive Substances Act 2016 is debated. Noopept is psychoactive in the broad sense (it produces a cognitive effect) and would arguably fall under the PSA, though there has been no test case or formal MHRA position specifically on Noopept. Most UK supplement retailers stopped selling Noopept after the PSA came into force in 2016, but it remains widely available from research-chemical sources and as a "nootropic supplement" through some EU vendors. WADA: not on the Prohibited List. US: not FDA-approved as a drug or supplement; some states have restricted sale.

Noopept vs Dihexa

Noopept and Dihexa are both cognitive-enhancement compounds with BDNF-related mechanisms but otherwise very different. Noopept is a small molecule dipeptide ester acting via AMPA glutamate receptor modulation plus BDNF/NGF upregulation, producing acute glutamatergic cognitive effects within hours and cumulative trophic effects over weeks. Dihexa is a true peptide acting via HGF/c-Met to drive direct synaptogenic structural change with effects building over weeks. Noopept is orally bioavailable at low milligram doses; Dihexa is orally bioavailable at higher milligram doses. Noopept has the more diverse mechanism (AMPA + trophic factors); Dihexa has the more targeted synaptogenic mechanism. For users seeking acute cognitive sharpening with a familiar oral small-molecule profile, Noopept is the more practical choice. For users seeking sustained structural cognitive plasticity, Dihexa is more targeted.

Stacking with Dihexa

Noopept is one of the most-stacked nootropics in any combination protocol. Common combinations: Noopept + Alpha-GPC (or CDP-choline) — the canonical pairing, adding a choline source to support the cholinergic component of Noopept's effect and reduce the headache that some users get from cholinergic depletion; Noopept + Modafinil for high-intensity work blocks; Noopept + L-theanine for calm cognitive lift; Noopept + Lion's Mane for combined NGF amplification. With Dihexa the rationale is complementary mechanisms — Noopept for acute glutamatergic cognitive engagement, Dihexa for structural synaptogenic reinforcement. No published interaction data, but the mechanisms (AMPA receptor modulation vs HGF/c-Met activation) do not compete.

Frequently Asked Questions

On a milligram-for-milligram basis, yes — Noopept is active at 10-30 mg doses where piracetam is active at 800-4800 mg. This is a receptor affinity statement; it does not mean Noopept is 1000x more clinically effective. The two have similar effect sizes at their respective clinical doses.

The legal status is debated. Noopept is not controlled and not licensed as a medicine, but the Psychoactive Substances Act 2016 may apply. Most UK supplement retailers stopped selling Noopept in 2016; it remains widely available from research-chemical sources.

The most common cause is cholinergic depletion from increased acetylcholine turnover. Adding a choline source (Alpha-GPC, CDP-choline) usually resolves the headache.

Yes, and many users prefer sublingual administration for slightly better bioavailability and faster onset. Place the powder or dissolved liquid under the tongue and hold for 1-2 minutes before swallowing.

Acute effects last 3-4 hours per dose. Cumulative cognitive effects build over 7-14 days of consistent dosing.

No published interaction data exists, but the mechanisms (AMPA modulation vs HGF/c-Met activation) do not compete and the combination is mechanistically reasonable.

The Bottom Line

Noopept is the most-validated Russian nootropic small molecule, with 30+ years of clinical use, a defined dual mechanism (AMPA modulation plus BDNF/NGF upregulation), and a clean acute cognitive effect at convenient oral doses. The UK legal position is ambiguous post-2016 PSA. Mechanistically distinct from Dihexa, Noopept is a complementary cognitive enhancement tool for users seeking an acute oral glutamatergic effect alongside Dihexa's structural synaptogenic action.